Connecta Therapeutics
Spain · Biotech · Healthtech
Connecta Therapeutics develops small-molecule treatments for neurological disorders, including CTH120, a clinical-stage candidate for Fragile X syndrome.
Product and development
Connecta Therapeutics is developing CTH120, a small-molecule neuroplasticity modulator intended as a potential disease-modifying treatment for Fragile X syndrome. The candidate is being evaluated in an ongoing Phase IIa clinical trial in adult men, with the study assessing safety, tolerability and effectiveness.
The company’s work is aimed at patients with Fragile X syndrome and the clinicians who treat them. Connecta is preparing further pediatric development; CTH120 remains an investigational medicine, and the company’s September financing is intended to support the ongoing clinical program.
- Product focus
- CTH120 clinical program for Fragile X syndrome
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Clinical development financing | €3.1M | Clave Capital — LeadCDTI Innvierte — ParticipantInveready — ParticipantProus Institute for Biomedical Research — Participant |